Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results.

Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Deconinck N, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Furgerson M, Asher DR, Vivien M, Sun Y, Murphy AP, Pordeli P, Torre CO, Manfrini M, Gerber M, Rodino-Klapac LR, EMBARK Study Group

Open source

DOI: 10.1007/s40120-026-01059-y
Published: 2026 Oct 27
Container: Neurology and therapy
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40120-026-01059-y,
  title = {Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results.},
  author = {Mendell JR and Muntoni F and McDonald CM and Mercuri EM and Deconinck N and Ciafaloni E and Komaki H and Leon-Astudillo C and Nascimento A and Proud C and Schara-Schmidt U and Veerapandiyan A and Zaidman CM and Furgerson M and Asher DR and Vivien M and Sun Y and Murphy AP and Pordeli P and Torre CO and Manfrini M and Gerber M and Rodino-Klapac LR and EMBARK Study Group},
  year = {2026},
  journal = {Neurology and therapy},
  doi = {10.1007/s40120-026-01059-y},
  url = {https://doi.org/10.1007/s40120-026-01059-y}
}

RIS

TY  - JOUR
TI  - Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results.
AU  - Mendell JR
AU  - Muntoni F
AU  - McDonald CM
AU  - Mercuri EM
AU  - Deconinck N
AU  - Ciafaloni E
AU  - Komaki H
AU  - Leon-Astudillo C
AU  - Nascimento A
AU  - Proud C
AU  - Schara-Schmidt U
AU  - Veerapandiyan A
AU  - Zaidman CM
AU  - Furgerson M
AU  - Asher DR
AU  - Vivien M
AU  - Sun Y
AU  - Murphy AP
AU  - Pordeli P
AU  - Torre CO
AU  - Manfrini M
AU  - Gerber M
AU  - Rodino-Klapac LR
AU  - EMBARK Study Group
PY  - 2026
JO  - Neurology and therapy
DO  - 10.1007/s40120-026-01059-y
UR  - https://doi.org/10.1007/s40120-026-01059-y
ER  -

APA

JR, M., F, M., CM, M., EM, M., N, D., E, C., H, K., C, L., A, N., C, P., U, S., A, V., CM, Z., M, F., DR, A., M, V., Y, S., AP, M., P, P., CO, T., M, M., M, G., LR, R., & Group, E. S. (2026). Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results.. Neurology and therapy. https://doi.org/10.1007/s40120-026-01059-y

Source records

pubmed · retrieved 2026-11-10T11:14:02.244Z